Objective To evaluate the effect of Chinese medicine(CM)treatment on survival time and quality of life(QOL)in patients with small cell lung cancer(SCLC).Methods This was an exploratory and prospective clinical observa...Objective To evaluate the effect of Chinese medicine(CM)treatment on survival time and quality of life(QOL)in patients with small cell lung cancer(SCLC).Methods This was an exploratory and prospective clinical observation.Patients diagnosed with SCLC receiving CM treatment were included and followed up every 3 months.The primary outcome was overall survival(OS),and the secondary outcomes were progression-free survival(PFS)and QOL.Results A total of 136 patients including 65 limited-stage SCLC(LS-SCLC)patients and 71 extensive-stage SCLC(ES-SCLC)patients were analyzed.The median OS of ES-SCLC patients was 17.27 months,and the median OS of LS-SCLC was 40.07 months.The survival time was 16.27 months for SCLC patients with brain metastasis,9.83 months for liver metastasis,13.43 months for bone metastasis,and 18.13 months for lung metastasis.Advanced age,pleural fluid,liver and brain metastasis were risk factors,while longer CM treatment duration was a protective factor.QOL assessment indicated that after 6 months of CM treatment,scores increased in function domains and decreased in symptom domains.Conclusion CM treatment might help prolong OS of SCLC patients.Moreover,CM treatment brought the trend of symptom amelioration and QOL improvement.These results provide preliminary evidence for applying CM in SCLC multi-disciplinary treatment.展开更多
Objective： To determine whether additional Chinese medicine（CM） could prolong survival and improve the quality of life（QOL） in patients with advanced non-small cell lung cancer（NSCLC） compared with Western medi...Objective： To determine whether additional Chinese medicine（CM） could prolong survival and improve the quality of life（QOL） in patients with advanced non-small cell lung cancer（NSCLC） compared with Western medicine（WM） alone. Methods： This was a multicenter, prospective cohort study. A total of 474 hospitalized patients with stage Ⅲ–Ⅳ NSCLC were recruited and divided into 2 groups. Patients in the WM group received radiotherapy, chemotherapy, and optimal supportive therapy according to the National Comprehensive Cancer Network（NCCN） guidelines. In the integrative medicine（IM） group, individualized CM（Chinese patent medicines and injections） and WM were administered. The primary end point was overall survival, and the secondary end points were time to disease progression, adverse events, and QOL. Follow-up clinical examinations and chest radiography were performed every 2 months. Results： The median survival was 16.60 months in the IM group and 13.13 months in the WM group（P〈0.01）. The incidences of loss of appetite, nausea, and vomiting in the IM group were significantly lower than those in the WM group（P〈0.05）. The QOL based on Functional Assessment of Cancer Therapy-Lung in the IM group was markedly higher than that in the WM group at the fourth course（P〈0.05）. Conclusions： Additional CM may prolong survival and improve the QOL patients with NSCLC. The adverse effects of radio-and chemotherapy may be attenuated as CM is used in combination with conventional treatments.展开更多
Objective：To assist decision-makers interpret and choose among conflicting meta-analyses,as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping m...Objective：To assist decision-makers interpret and choose among conflicting meta-analyses,as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping meta-analyses regarding Shenyi Capsule（参一胶囊,SC） plus chemotherapy versus chemotherapy of non-small cell lung cancer（NSCLC）.Methods：A literature search was conducted to select systematic reviews comparing SC plus chemotherapy with chemotherapy for NSCLC.Meta-analyses only composed of randomized controlled trials（RCTs） met the inclusion criteria.Two authors individually estimated the quality of meta-analysis and extracted data.The Jadad decision algorithm was applied to guarantee which meta-analysis provided the best original evidence.Results：A total of 5 meta-analyses were included.All the studies composed of RCTs or quasi-RCTs and were regarded as level-Ⅱ evidence.The scores of the Assessment of Multiple Systematic Reviews ranged from 3 to 6（median 4）.A high-quality meta-analysis with more RCTs was chosen,which suggested that SC plus chemotherapy could increase incidence of short-term efficacy,improve the quality of life and survival rate in comparison to chemotherapy.However,there was no statistically significant difference between SC plus chemotherapy and chemotherapy regarding chemotherapy-induced side effect,such as liver and kidney function obstacle,leukopenia,hemoglobin decrement and gastrointestinal adverse reaction.Conclusions：Based on the best available evidence,treatment effect of SC plus chemotherapy was better than chemotherapy and did not increase side effects.Therefore,SC plus chemotherapy may be superior to chemotherapy for treating NSCLC.However,due to some limitations,SC plus chemotherapy should be cautiously considered,and further high-quality meta-analyses are needed.展开更多
Objective：To assess the efficacy of Chinese medicine（CM） on patients with pancreatic cancer（PC） in a retrospective population-based study.Methods：Between January 1,2013,and August 30,2016,according to whether re...Objective：To assess the efficacy of Chinese medicine（CM） on patients with pancreatic cancer（PC） in a retrospective population-based study.Methods：Between January 1,2013,and August 30,2016,according to whether received Western medicine treatment,the patients were included into either integrative medicine（IM） group or CM group.All enrolled patients were orally administrated with Gexia Zhuyu Decoction（膈下逐瘀汤） or Liujun Ermu Decoction（六君二母汤） by syndrome differentiation,twice a day,last for at least 2 months.The primary end point was overall survival（OS）.Results：A total of 174 patients with PC were enrolled in this study.In stage Ⅰ/Ⅱ,the median OS was 20.5 months in the IM group [95% confidence interval（CI）,12.499 to 28.501] and 11.17 months in the CM group（95% CI,5.160 to 17.180,P=0.015）.The 1-and 2-year survival rates for the two groups were 47.0%,40.0% and 21.0%,21.0%,respectively.In stage Ⅲ/Ⅳ,median OS was 13.53 months（95% CI,8.665 to 18.395） in the IM group versus 6.4 months（95% CI,0.00 to 15.682） in the CM group,respectively（P=0.32）.The 1-and 2-year survival rate for the IM and CM groups were 27.0%,7.0% and 20.0%,2.0%,respectively.Conclusions：Intervention of CM contributes to the different survival benefits for PC in different stages.Multimodality treatment might be a promising strategy for PC patients in early stage.While,in advanced stage,CM might be an alternative candidate for PC patients.展开更多
基金Surpported by National Natural Science Foundation of China(No.81673797)Beijing Municipal Natural Science Foundation(No.7182142)。
文摘Objective To evaluate the effect of Chinese medicine(CM)treatment on survival time and quality of life(QOL)in patients with small cell lung cancer(SCLC).Methods This was an exploratory and prospective clinical observation.Patients diagnosed with SCLC receiving CM treatment were included and followed up every 3 months.The primary outcome was overall survival(OS),and the secondary outcomes were progression-free survival(PFS)and QOL.Results A total of 136 patients including 65 limited-stage SCLC(LS-SCLC)patients and 71 extensive-stage SCLC(ES-SCLC)patients were analyzed.The median OS of ES-SCLC patients was 17.27 months,and the median OS of LS-SCLC was 40.07 months.The survival time was 16.27 months for SCLC patients with brain metastasis,9.83 months for liver metastasis,13.43 months for bone metastasis,and 18.13 months for lung metastasis.Advanced age,pleural fluid,liver and brain metastasis were risk factors,while longer CM treatment duration was a protective factor.QOL assessment indicated that after 6 months of CM treatment,scores increased in function domains and decreased in symptom domains.Conclusion CM treatment might help prolong OS of SCLC patients.Moreover,CM treatment brought the trend of symptom amelioration and QOL improvement.These results provide preliminary evidence for applying CM in SCLC multi-disciplinary treatment.
基金Supported by National Key Technologies Research and Development Program for the 11th Five-Year Plan(No.2006BAI04A05)
文摘Objective： To determine whether additional Chinese medicine（CM） could prolong survival and improve the quality of life（QOL） in patients with advanced non-small cell lung cancer（NSCLC） compared with Western medicine（WM） alone. Methods： This was a multicenter, prospective cohort study. A total of 474 hospitalized patients with stage Ⅲ–Ⅳ NSCLC were recruited and divided into 2 groups. Patients in the WM group received radiotherapy, chemotherapy, and optimal supportive therapy according to the National Comprehensive Cancer Network（NCCN） guidelines. In the integrative medicine（IM） group, individualized CM（Chinese patent medicines and injections） and WM were administered. The primary end point was overall survival, and the secondary end points were time to disease progression, adverse events, and QOL. Follow-up clinical examinations and chest radiography were performed every 2 months. Results： The median survival was 16.60 months in the IM group and 13.13 months in the WM group（P〈0.01）. The incidences of loss of appetite, nausea, and vomiting in the IM group were significantly lower than those in the WM group（P〈0.05）. The QOL based on Functional Assessment of Cancer Therapy-Lung in the IM group was markedly higher than that in the WM group at the fourth course（P〈0.05）. Conclusions： Additional CM may prolong survival and improve the QOL patients with NSCLC. The adverse effects of radio-and chemotherapy may be attenuated as CM is used in combination with conventional treatments.
文摘Objective：To assist decision-makers interpret and choose among conflicting meta-analyses,as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping meta-analyses regarding Shenyi Capsule（参一胶囊,SC） plus chemotherapy versus chemotherapy of non-small cell lung cancer（NSCLC）.Methods：A literature search was conducted to select systematic reviews comparing SC plus chemotherapy with chemotherapy for NSCLC.Meta-analyses only composed of randomized controlled trials（RCTs） met the inclusion criteria.Two authors individually estimated the quality of meta-analysis and extracted data.The Jadad decision algorithm was applied to guarantee which meta-analysis provided the best original evidence.Results：A total of 5 meta-analyses were included.All the studies composed of RCTs or quasi-RCTs and were regarded as level-Ⅱ evidence.The scores of the Assessment of Multiple Systematic Reviews ranged from 3 to 6（median 4）.A high-quality meta-analysis with more RCTs was chosen,which suggested that SC plus chemotherapy could increase incidence of short-term efficacy,improve the quality of life and survival rate in comparison to chemotherapy.However,there was no statistically significant difference between SC plus chemotherapy and chemotherapy regarding chemotherapy-induced side effect,such as liver and kidney function obstacle,leukopenia,hemoglobin decrement and gastrointestinal adverse reaction.Conclusions：Based on the best available evidence,treatment effect of SC plus chemotherapy was better than chemotherapy and did not increase side effects.Therefore,SC plus chemotherapy may be superior to chemotherapy for treating NSCLC.However,due to some limitations,SC plus chemotherapy should be cautiously considered,and further high-quality meta-analyses are needed.
基金Supported by the National Natural Science Foundation of China(No.81673797)
文摘Objective：To assess the efficacy of Chinese medicine（CM） on patients with pancreatic cancer（PC） in a retrospective population-based study.Methods：Between January 1,2013,and August 30,2016,according to whether received Western medicine treatment,the patients were included into either integrative medicine（IM） group or CM group.All enrolled patients were orally administrated with Gexia Zhuyu Decoction（膈下逐瘀汤） or Liujun Ermu Decoction（六君二母汤） by syndrome differentiation,twice a day,last for at least 2 months.The primary end point was overall survival（OS）.Results：A total of 174 patients with PC were enrolled in this study.In stage Ⅰ/Ⅱ,the median OS was 20.5 months in the IM group [95% confidence interval（CI）,12.499 to 28.501] and 11.17 months in the CM group（95% CI,5.160 to 17.180,P=0.015）.The 1-and 2-year survival rates for the two groups were 47.0%,40.0% and 21.0%,21.0%,respectively.In stage Ⅲ/Ⅳ,median OS was 13.53 months（95% CI,8.665 to 18.395） in the IM group versus 6.4 months（95% CI,0.00 to 15.682） in the CM group,respectively（P=0.32）.The 1-and 2-year survival rate for the IM and CM groups were 27.0%,7.0% and 20.0%,2.0%,respectively.Conclusions：Intervention of CM contributes to the different survival benefits for PC in different stages.Multimodality treatment might be a promising strategy for PC patients in early stage.While,in advanced stage,CM might be an alternative candidate for PC patients.
